Navigation Links
Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
Date:10/10/2007

PALO ALTO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today the appointment of its C.E.O., Belinda Tsao-Nivaggioli, Ph.D., to the additional role of Chairman of the Company's Board of the Directors. Dr. Tsao- Nivaggioli succeeds Nasser Menhall, who recently resigned from the Board to focus his time on other business ventures.

"I want to take this opportunity to thank Nasser for his many contributions and his invaluable leadership over many years and I wish him best of luck in his new ventures," stated Dr. Tsao-Nivaggioli. "I appreciate the Board of Directors' vote of confidence and I continue to be proud to be associated with this organization and its people. I look forward to leading this Company and to further leveraging our cellular energy technology to develop and commercialize pharmaceutical and dermaceutical products."

Prior to her current roles of CEO and Chairman, Dr. Tsao-Nivaggioli was Avicena's chief operating officer from 2002 to 2004. During her tenure with the Company, Dr. Tsao-Nivaggioli has expanded its intellectual property portfolio and built a substantial pipeline of pharmaceutical products, including drug candidates for the treatment of neurological disorders such as ALS, Huntington's and Parkinson's Disease. Dr. Tsao-Nivaggioli is also credited with solidifying the Company's relationship with the National Institutes of Health (NIH) as well as developing the Company's dermaceutical programs.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:

The Ruth Group (on behalf of Avicena Group)

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com or jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Avicena to Advance Huntingtons Disease Clinical Program into Phase III
2. Study casts doubt on keyboard ills
3. Who Board To Discuss Asian Tsunami Related Health Issues
4. Abdominal Crunches Not The Best Option For Wash Board Abs.
5. Computer Keyboards In Hospitals Could Spread Infection To Patients
6. Flu, Boarded A Ship?
7. Skateboarding to health
8. Shangai Citizens to Monitor Billboards
9. Budhia Is Fine, Government-constituted Medical Board Reports False
10. Pharmacy Board Says Pharmacists Have Right To Refuse Morning-After Pill
11. 115 people on board a cruise liner taken ill due to suspected Norovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... The Ellis Agency, ... with the Epilepsy Foundation in a community wide charity event with the goal of ... Sunde, a young local woman who lives with epilepsy, recently launched a charity campaign ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... Pace Analytical, a company of over 2,000 employees and a leader in environmental ... Sciences, further solidifying their position as the top American owned and operated environmental ... ... Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative full ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
Breaking Medicine Technology: